Champions Oncology Inc (OTCMKTS:CSBR) issued its earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, Bloomberg Earnings reports. The business had revenue of $5.03 million for the quarter. Champions Oncology had a negative return on equity of 796.94% and a negative net margin of 65.16%.
Champions Oncology (OTCMKTS CSBR) traded up 11.49% on Friday, hitting $3.59. The stock had a trading volume of 99,151 shares. Champions Oncology has a 1-year low of $1.48 and a 1-year high of $4.79. The company has a 50-day moving average price of $3.09 and a 200-day moving average price of $2.83. The stock’s market capitalization is $39.43 million.
A hedge fund recently raised its stake in Champions Oncology stock. GRT Capital Partners L.L.C. increased its position in Champions Oncology Inc (OTCMKTS:CSBR) by 70.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,064 shares of the biotechnology company’s stock after buying an additional 17,000 shares during the quarter. GRT Capital Partners L.L.C. owned 0.37% of Champions Oncology worth $106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, ValuEngine raised Champions Oncology from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd.
About Champions Oncology
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.